Obesity Prevention in Children and Young People Treated for Acute Lymphoblastic Leukaemia with ALLTogether

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age5-21
SponsorUniversity of Exeter

About this trial

Background Leukaemia is the most common cancer in children with 800 diagnoses per year in England. To survive, children need strong treatments like chemotherapy and steroids given usually through clinical trials. The current trial used by the NHS is called ALLTogether. Fifty percent of children become obese during treatment due to increased hunger, cravings for junk foods and lack of physical activity. Obesity raises the chance of cancer relapse by 31%, makes treatment side-effects worse and makes it harder to kill off leukaemia cells, which affects how well children do during treatment, as indicated by minimal residual disease, a key predictor of prognosis.

Aims and Objectives This study (called BREVARY) aims to see if we can successfully provide personalised diet and physical activity with behaviour support for children and young people with leukaemia who are being treated with the ALLTogether trial. It will help us figure out if we can perform a bigger study, if this programme could reduce obesity and side-effects and improve survival and wellbeing.

How it will be done We plan to randomly assign participants to one of three groups; one group will get both a diet and physical activity plan, another will get only a diet plan, and the last group will receive standard care. This will take place in Hospital Infantil Universitario Nino Jesus, Madrid and Bristol Royal Hospital for Children and Southwest England NHS-sites. The diet and exercise plans will be created in partnership with the children and their families and delivered online or during regular hospital visits. The diet will follow healthy eating guidelines, consider personal food preferences (including cultural and religious needs), treatment side-effects and personal finances. Assessments of fitness and strength will be taken to plan personalised activities. During the study, the following data will also be collected: weight, height, body fat, diet, biomarkers, microbiome, muscle strength and wellbeing at three different times. "One to one" interviews will be conducted at the end to obtain feedback on their experiences with BREVARY.

This study aims to find out if children and their families/carers are willing to participate in BREVARY, if enough people sign up and stay until the end and if our interventions and health measurements are appropriate.

Potential Impact The results will help determine if a larger study can be performed, if changes are needed and what the cost will be. The study will be disseminated through networks, targeting underserved communities, healthcare professionals and affected families using accessible platforms to spread the word.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

CYP aged between 5 - 21 years.

Newly diagnosed or relapsed CYP_ALL treated in University Hospital Bristol and Weston NHS Foundation Trust and Hospital Infantil Universitario Nino Jesus, Madrid

Within two weeks of being recruited to ALLTogether.

Treated with curative intent.

Disqualifiers

CYP not partaking in ALLTogether.

CYP treated with palliative intent.

Those excluded by healthcare professionals or clinical reasons

Trial design

Design model

Parallel

Treatments tested in this trial

  • Diet

    Behavioral

    Individualised dietary intervention

  • Diet and physical activity

    Behavioral

    Obesity prevention: Diet, Diet and physical activity and standard care

Treatment groups

90 Participants
are divided into 3 treatment groups
Group A: DietExperimental treatment 1 intervention
Group B: Diet and Physical ActivityExperimental treatment 1 intervention
Group C: Standard CareNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Minimal Residual Disease

Candidate Primary Outcome (feasibility study). Hospital own's laboratory assay

Time frame
initial assessment, day 29, day 50 and day 78
2

Muscle and fat mass

Candidate primary outcome, Multifrequency BIA FFM and FM percentage Impedance Reactant

Time frame
Initial assessment, at 29 days, at 3 months, at 6 months
3

Body Mass Index Z score

Candidate Primary Outcome Calculated from weight and height (weight/height\^2) WHO BMI Z score (scale score) Z-Score Range Nutritional Status \< -3 SD: Severe undernutrition (Severely underweight, stunted, or wasted) * -3 SD and \< -2 SD: Moderate undernutrition (Underweight, stunted, or wasted) * -2 SD and ≤ +1 SD: Healthy weight (Normal nutritional status) * +1 SD and ≤ +2 SD: Overweight * +2 SD: Obese

Time frame
initial assessment, at day 29, at 3 months and at 6 months
4

Quality of Life

Candidate Primary outcome (Quality of Life: PedQL-Cancer Module questionnaire) The PedsQL-Cancer Module includes multiple subscales that address specific areas of functioning and challenges related to cancer, such as: Pain and hurt, Nausea, Procedural anxiety, Treatment anxiety, Worry, Cognitive problems, Perceived physical appearance, Communication. To calculate scores, the items are reverse scored and linearly transformed to a Original Response Reverse Score (Transformed Score) 0 = Never 100 1. = Almost Never 75 2. = Sometimes 50 3. = Often 25 4. = Almost Always 0 Scores are reverse, thus higher scores indicate better health-related quality of life or fewer reported problems. Mean scores are calculated for each subscale by summing the item scores and dividing by the number of items answered. If more than 50% of the items in a subscale are missing, the subscale score is not computed.

Time frame
initial assessment, at 3 months and at 6 months

Secondary outcomes

1

Leptin

Candidate secondary outcomes for future RCT: leptin (abcam assay)

Time frame
Initial assessment, at day 29, at 3 months and at 6 months
2

Food group indicators and nutrient intake

Candidate Secondary Outcome for RCT multiple pass 24-hour recall Food groups (Eatwell Guide and A healthy eating index score (HEI)) Macronutrients and micronutrients (analysed in Nutritics) compared to UK Dietary Recommended Daily Intake (DRVs 1991, SANC 2011) and Spanish Ingestas Nutricionales de Referencia (AESAN 2019)

Time frame
Initial assessment, at day 29, at 3 months and at 6 months
3

Physical activity levels min/day

Candidate secondary outcome for RCT GENEActiv accelerometers (min/day) 5 week days, 2 weekend days (minimum recorded 10 hours)

Time frame
Initial assessment, at 3 months and at 6 months
4

Handgrip strength

Candidate secondary outcome for RCT hand-held hydraulic dynamometer

Time frame
Initial assessment, at day 29, at 3 months and at 6 months

Other outcomes

1

Characterisation of gut microbiome: Diversity

Outcome from 16sRNA sequencing: alpha and beta bacteria.

Time frame
At 0, day 29, 3 months and 6 months
2

Gut microbiome: Relative abundance

Relative abundances (comparison between groups: alpha and beta bacteria)

Time frame
At 0, day 29, 3 months and 6 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: